Apollo Neuroscience CEO and leadership

Kathryn Fantauzzi is the co-founder & CEO of Apollo Neuroscience, which has developed the first scientifically-validated wearable technology that actively improves energy, focus & sleep. Originally invented by a team of physicians and neuroscientists at the University of Pittsburgh, the Apollo uses a novel touch therapy that signals safety to the brain, accelerating stress recovery and supporting mental and physical resilience.

Experienced in early-stage tech commercialization, Kathryn joined the University of Pittsburgh research team in 2016 to raise funding to conduct clinical research on the Apollo discovery and accelerate the health care technology’s availability to the public. After clinical trials demonstrated Apollo’s efficacy, Kathryn founded Apollo Neuroscience, raised $4.5 Million and alongside her co-founder (and husband!), Dr. Dave Rabin, brought the Apollo to market in January 2020.

Kathryn is dedicated to innovation: getting good science out of the lab and into people’s lives. As CEO, Kathryn has built a highly-skilled team of physicians, researchers, engineers, and designers to transform the Apollo technology from a futuristic concept into a simple but powerful tool. She spearheaded the company’s go-to-market strategy, cultivated a network of investors, researchers and partners, while leading the launch of the flagship product.

Kathryn has deep experience in incubating early-stage technology startups. Prior to founding Apollo, she helped develop and launch a $20M tech commercialization accelerator through the NY State Energy Research & Development Authority. In this capacity, she identified promising academic innovations, evaluated their market potential, and funded their development. She also led an initiative to incentivize investment in sustainability, called Green Jobs Green NY, where she oversaw a $13M funding pool and approved projects for financing.

Born & raised in upstate New York, Kathryn holds a B.A. from Smith College and a Master of Public Administration (MPA), with a focus on behavioral economics and finance, from the Rockefeller College of Public Affairs and Policy.

She and her co-founder are happily married, and split their time between Monterey, California and Pittsburgh, PA. Kathryn grew up in a big family and loves the outdoors. When she isn’t leading the charge on digital therapeutics, you’ll find her whipping up food for family & friends, hosting get-to-togethers, hiking the California coastline, and biking, swimming, sailing or skiing.

Dr. David Rabin, MD, PhD, is a neuroscientist, board-certified psychiatrist, health tech entrepreneur & inventor who has been studying the impact of chronic stress in humans for more than a decade. He is the co-founder & chief innovation officer at Apollo Neuroscience, which has developed the first scientifically-validated wearable technology that actively improves energy, focus & relaxation, using a novel touch therapy that signals safety to the brain.Dr. Rabin has always been fascinated by consciousness and our inherent ability to heal ourselves from injury and illness. As such, he has specifically focused his research on the clinical translation of non-invasive therapies for patients with treatment-resistant illnesses like PTSD and substance use disorders.Dr. Rabin is the co-founder and executive director of the Board of Medicine, a 501(c)(3) nonprofit organization of physicians and scientists establishing the first peer-reviewed, evidence-based clinical guidelines for the production and safe use of currently unregulated alternative medicines, including plant medicines. The Board of Medicine trains and certifies healthcare providers, as well providing quality control standards for complementary and alternative medicines to support high-quality clinical research and best practices in harm-reduction.In addition to his clinical psychiatry practice (The Apollo Clinic - DrDave.io) focused on treatment-resistant mental illnesses and psychedelic-assisted psychotherapy, Dr. Rabin is currently conducting research on the epigenetic regulation of trauma responses and recovery to elucidate the mechanism of psychedelic-assisted psychotherapy and the neurobiology of belief. Dr. Rabin is serves a Board Member of Semper Fi Odyssey (SFO)/Outdoor Odyssey serving traumatized active duty military, Veterans, and children, a Venture Partner of the Noetic Psychedelic Fund, Medical Director of The Apollo Clinic, and the co-host and co-founder of The Psychedelic News Hour on Clubhouse, soon to be one of the first science podcasts about psychedelic medicines.Dr. Rabin received his MD in medicine and PhD in neuroscience from Albany Medical College and specialized in psychiatry with a distinction in research at Western Psychiatric Institute & Clinic at the University of Pittsburgh Medical Center.

Highly experienced technology executive and Chief Financial Officer, who has led a start-up to successful IPO as CFO. Software and internet sector industry experience (SaaS, online marketplace and digital marketing background). Sixteen years as CFO of a public ecommerce company: ten as a public company that reached |$1B market cap. Operational and growth focused: early stage private to public. Former partner with a top-tier international public accounting firm. Recognized firm-wide global software and SaaS industry expert. Current Board Member and Audit Committee Chair of public internet company. CPA (Inactive) in the state of California.

Kathryn Fantauzzi is the co-founder & CEO of Apollo Neuroscience, which has developed the first scientifically-validated wearable technology that actively improves energy, focus & sleep. Originally invented by a team of physicians and neuroscientists at the University of Pittsburgh, the Apollo uses a novel touch therapy that signals safety to the brain, accelerating stress recovery and supporting mental and physical resilience.

Experienced in early-stage tech commercialization, Kathryn joined the University of Pittsburgh research team in 2016 to raise funding to conduct clinical research on the Apollo discovery and accelerate the health care technology’s availability to the public. After clinical trials demonstrated Apollo’s efficacy, Kathryn founded Apollo Neuroscience, raised $4.5 Million and alongside her co-founder (and husband!), Dr. Dave Rabin, brought the Apollo to market in January 2020.

Kathryn is dedicated to innovation: getting good science out of the lab and into people’s lives. As CEO, Kathryn has built a highly-skilled team of physicians, researchers, engineers, and designers to transform the Apollo technology from a futuristic concept into a simple but powerful tool. She spearheaded the company’s go-to-market strategy, cultivated a network of investors, researchers and partners, while leading the launch of the flagship product.

Kathryn has deep experience in incubating early-stage technology startups. Prior to founding Apollo, she helped develop and launch a $20M tech commercialization accelerator through the NY State Energy Research & Development Authority. In this capacity, she identified promising academic innovations, evaluated their market potential, and funded their development. She also led an initiative to incentivize investment in sustainability, called Green Jobs Green NY, where she oversaw a $13M funding pool and approved projects for financing.

Born & raised in upstate New York, Kathryn holds a B.A. from Smith College and a Master of Public Administration (MPA), with a focus on behavioral economics and finance, from the Rockefeller College of Public Affairs and Policy.

She and her co-founder are happily married, and split their time between Monterey, California and Pittsburgh, PA. Kathryn grew up in a big family and loves the outdoors. When she isn’t leading the charge on digital therapeutics, you’ll find her whipping up food for family & friends, hosting get-to-togethers, hiking the California coastline, and biking, swimming, sailing or skiing.

Dr. David Rabin, MD, PhD, is a neuroscientist, board-certified psychiatrist, health tech entrepreneur & inventor who has been studying the impact of chronic stress in humans for more than a decade. He is the co-founder & chief innovation officer at Apollo Neuroscience, which has developed the first scientifically-validated wearable technology that actively improves energy, focus & relaxation, using a novel touch therapy that signals safety to the brain.Dr. Rabin has always been fascinated by consciousness and our inherent ability to heal ourselves from injury and illness. As such, he has specifically focused his research on the clinical translation of non-invasive therapies for patients with treatment-resistant illnesses like PTSD and substance use disorders.Dr. Rabin is the co-founder and executive director of the Board of Medicine, a 501(c)(3) nonprofit organization of physicians and scientists establishing the first peer-reviewed, evidence-based clinical guidelines for the production and safe use of currently unregulated alternative medicines, including plant medicines. The Board of Medicine trains and certifies healthcare providers, as well providing quality control standards for complementary and alternative medicines to support high-quality clinical research and best practices in harm-reduction.In addition to his clinical psychiatry practice (The Apollo Clinic - DrDave.io) focused on treatment-resistant mental illnesses and psychedelic-assisted psychotherapy, Dr. Rabin is currently conducting research on the epigenetic regulation of trauma responses and recovery to elucidate the mechanism of psychedelic-assisted psychotherapy and the neurobiology of belief. Dr. Rabin is serves a Board Member of Semper Fi Odyssey (SFO)/Outdoor Odyssey serving traumatized active duty military, Veterans, and children, a Venture Partner of the Noetic Psychedelic Fund, Medical Director of The Apollo Clinic, and the co-host and co-founder of The Psychedelic News Hour on Clubhouse, soon to be one of the first science podcasts about psychedelic medicines.Dr. Rabin received his MD in medicine and PhD in neuroscience from Albany Medical College and specialized in psychiatry with a distinction in research at Western Psychiatric Institute & Clinic at the University of Pittsburgh Medical Center.